Re: The Asshat Thread
Posted: August 22 16, 2:33 pm
Again, Clay Travis.
A Message Board Dedicated to Discussing St. Louis Cardinals Baseball!
https://gatewayredbirds.org/forum/
What did he do now? That guy is the worst.lukethedrifter wrote:Again, Clay Travis.
The Brazilians took it up a big notch when they started issuing orders to pull people off their flights over it. Lochte and gang were in the wrong, but the armed negotiation wasn't a good look either and the subsequent official reaction seemed over the top defensive.lukethedrifter wrote:Just excusing Lochte. In the big picture it's not that big of a deal but he's not a kid, it's not Spring Break, and he's the idiot that turned it into something. No one else.
EpiPen prices aren't the only thing to jump at Mylan. Executive salaries have also seen a stratospheric uptick.
Proxy filings show that from 2007 to 2015, Mylan CEO Heather Bresch's total compensation went from $2,453,456 to $18,931,068, a 671 percent increase. During the same period, the company raised EpiPen prices, with the average wholesale price going from $56.64 to $317.82, a 461 percent increase, according to data provided by Connecture.
In 2007 the company bought the rights to EpiPen, a device used to provide emergency epinephrine to stop a potentially fatal allergic reaction and began raising its price. In 2008 and 2009, Mylan raised the price by 5 percent. At the end of 2009 it tried out a 19 percent hike. The years 2010-2013 saw a succession of 10 percent price hikes.
Mmmmmmmmmpioneer98 wrote:Mylan CEO's Pay Rose Over 600 Percent as EpiPen Price Rose 400 PercentEpiPen prices aren't the only thing to jump at Mylan. Executive salaries have also seen a stratospheric uptick.
Proxy filings show that from 2007 to 2015, Mylan CEO Heather Bresch's total compensation went from $2,453,456 to $18,931,068, a 671 percent increase. During the same period, the company raised EpiPen prices, with the average wholesale price going from $56.64 to $317.82, a 461 percent increase, according to data provided by Connecture.
In 2007 the company bought the rights to EpiPen, a device used to provide emergency epinephrine to stop a potentially fatal allergic reaction and began raising its price. In 2008 and 2009, Mylan raised the price by 5 percent. At the end of 2009 it tried out a 19 percent hike. The years 2010-2013 saw a succession of 10 percent price hikes.
